Sarepta Shares Plummet On News Of Elevidys Patient Death

 
• By Joseph Haas

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.

Sarepta building
Sarepta faces new questions about DMD gene therapy Elevidys • Source: Shutterstock

More from Gene Therapies

More from Therapy Areas